Form 8-K - Current report:
SEC Accession No. 0001193125-24-241397
Filing Date
2024-10-23
Accepted
2024-10-23 06:05:02
Documents
17
Period of Report
2024-10-23
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d750511d8k.htm   iXBRL 8-K 67572
6 GRAPHIC g750511g00p19.jpg GRAPHIC 126847
7 GRAPHIC g750511g00p20.jpg GRAPHIC 102643
8 GRAPHIC g750511g00p21.jpg GRAPHIC 103264
  Complete submission text file 0001193125-24-241397.txt   1024825

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rvmdw-20241023.xsd EX-101.SCH 3911
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvmdw-20241023_def.xml EX-101.DEF 13294
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmdw-20241023_lab.xml EX-101.LAB 21820
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmdw-20241023_pre.xml EX-101.PRE 14198
19 EXTRACTED XBRL INSTANCE DOCUMENT d750511d8k_htm.xml XML 5511
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39219 | Film No.: 241387706
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)